Pharmacokinetics and Systemic Action
Sulfacarbamide (Urosulfanum) belongs to the sulfonamide group intended for resorptive action. Following oral administration, the drug is well absorbed from the gastrointestinal tract, enters the systemic circulation, and exerts a generalized therapeutic effect.
According to the pharmacokinetic classification based on the elimination half-life ($t_{1/2}$), sulfacarbamide is categorized as a short-acting agent ($t_{1/2} < 10$ hours).
A key metabolic feature of sulfacarbamide is that it undergoes minimal acetylation in the body. Unlike many other sulfonamides, it is excreted by the kidneys predominantly in its unchanged (free) form.
Indications for Use
The primary clinical target for this drug is urinary tract infections (UTIs).
Because the drug is excreted renally in its unchanged form, it retains its antibacterial activity throughout metabolism. This allows for consistently high active concentrations of the substance directly within the urine, ensuring a reliable therapeutic effect at the site of infection. Sulfethidole (ethazole) shares this property within the short-acting sulfonamide group—both agents are considered drugs of choice for UTIs.
Dosing Regimen and Formulations
The short half-life (less than 10 hours) requires frequent administration to maintain therapeutic concentrations in the blood and urine. Sulfacarbamide is typically administered 4–6 times daily.
It is available as powder and 0.5 g tablets.
Administration guidelines:
- Taken 30 minutes before meals.
- Day 1 of treatment: A loading dose is administered—an initial dose of 1.5–2.0 g, followed by a maintenance dose of 1.0 g every 4 hours.
- Day 2 onwards: Dosage is reduced to 1.0 g 4 times daily.
- Dosage limits: The maximum single dose (MSD) is 2.0 g, and the maximum daily dose (MDD) is 7.0 g.
Position in the Classification of Sulfonamides
To understand the pharmacokinetics of sulfacarbamide, it is useful to examine its place in the general classification of systemically active sulfonamides, categorized by elimination half-life ($t_{1/2}$):
- Short-acting ($t_{1/2} < 10$ h): In addition to sulfacarbamide (Urosulfanum), this group includes sulfanilamide (streptocide), sulfathiazole, sulfethidole (ethazole), and sulfadimidine. They require frequent administration.
- Intermediate-acting ($t_{1/2}$ 10–24 h): Sulfadiazine and sulfamethoxazole.
- Long-acting ($t_{1/2}$ 24–48 h): Sulfadimethoxine, sulfamonomethoxine, sulfamethoxypyridazine.
- Ultra-long-acting ($t_{1/2} > 48$ h): Sulfalene.
Thus, sulfacarbamide is a classic short-acting systemic agent requiring strict adherence to dosing intervals.